Isotechnika in license pact with Vifor Pharma

Isotechnika Pharma (TSX:ISA) has signed a global development and commercialization license agreement with Vifor Pharma, a member of the Swiss Galenica Group, for its lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications, covering the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong. While [...]

Donald Wyatt joins Isotechnika board

Donald Wyatt, the founder of consultancy The Wyatt Group, has been appointed a director of Isotechnika Pharma (TSX:ISA), serving as a representative of 3SBio (NASDAQ:SSRX), a Chinese biotech company. Mr. Wyatt is currently an advisor to 3SBio. He replaces Dr. David Chen, COO of 3SBio, who recently has taken on additional responsibilities that make it [...]

Isotechnika releases shareholder letter

In a letter to shareholders issued today, Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster explains the company’s decision to move its voclosporin drug into Phase 3 clinical trials for the prevention of kidney transplant rejection.  He outlines the market opportunity, the scientific rationale and the clinical support for the transplantation indication as well as laying [...]

Paladin, Isotechnika submit Voclera in Canada

Paladin Labs (TSX:PLB) and Isotechnika (TSX:ISA) have submitted Voclera, a treatment for moderate to severe psoriasis, for marketing approval in Canada. Voclera was discovered by Isotechnika and has been in development since the late 1990s. Paladin acquired the Canadian rights for Voclera from Isotechnika in June, 2009. “This submission is the culmination of almost 15 years [...]

FDA cancels meeting but review of Isotechnika’s voclosporin continues

The FDA has cancelled a June 28 dermatology and ophthalmology drugs advisory committee review of a new drug application by Isotechnika Pharma’s (TSX:ISA) partner Lux Biosciences for their voclosporin drug as a treatment of non-infectious uveitis. On its website, the FDA said the meeting was cancelled to allow time for the “resolution of several outstanding [...]

Isotechnika has a powerhouse franchise in voclosporin

Dr. Robert Foster still longs to make Isotechnika’s (TSX: ISA) lead drug, voclosporin, the standard of care in the field of preventing organ rejection in transplantation surgery. This may seem somewhat unusual, since voclosporin is currently being considered by regulators in North America and Europe to treat uveitis, a chronic inflammation of the eye that [...]

EMA accepts Isotechnika-Lux filing for eye drug

The European Medicines Agency has accepted a marketing application filed by Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, for voclosporin to treat non-infectious uveitis involving the posterior segment of the eye, the fourth leading cause of legal blindness in the industrialized world. “With the EMA acceptance of the dossier we now expect the review process to [...]

Isotechnika amends deal with Paladin Labs

Isotechnika Pharma’s (TSX: ISA) wholly owned subsidiary, Isotechnika Labs, has amended its agreement with Paladin Labs (TSX:PLB) on the remaining stake in the revenue stream from the Isodiagnostika business, which was sold to Paladin in mid-2009. Under the original deal, Isotechnika Labs was entitled to receive a revenue stream equivalent to 88% of the net [...]

Isotechnika partner files drug applications

Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has filed a new drug application with the FDA and a market authorization application with the European Medicines Agency for voclosporin, under the proposed brand name Luveniq. Voclosporin is a next generation calcineurin inhibitor to treat non-infectious uveitis, involving the posterior segment of the eye, a leading cause of [...]

Cash-rich Paladin on the acquisition trail

Paladin Labs (TSX:PLB) is sitting on a war chest of some $97 million that’s growing by the quarter and itching to be deployed. “We’re going to invest in opportunities with a high return on investment,” CEO Jonathan Goodman, says in an exclusive interview with biotuesdays.com.  “But I’m not going to bet the company on a [...]